137 related articles for article (PubMed ID: 31250562)
21. [Ibrutinib-associated atrial fibrillation : A therapeutic challenge].
Schmitt P; Demoulin R; Poyet R; Capilla E; Rohel G; Pons F; Jégo C; Sidibe S; Prevautel T; Druelle A; Brocq FX; Cellarier GR
Ann Cardiol Angeiol (Paris); 2022 Nov; 71(5):321-324. PubMed ID: 36115721
[TBL] [Abstract][Full Text] [Related]
22. Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study.
Mattiello V; Barone A; Giannarelli D; Noto A; Cecchi N; Rampi N; Cassin R; Reda G
Hematol Oncol; 2023 Aug; 41(3):363-370. PubMed ID: 36762406
[TBL] [Abstract][Full Text] [Related]
23. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.
Chai KL; Rowan G; Seymour JF; Burbury K; Carney D; Tam CS
Leuk Lymphoma; 2017 Dec; 58(12):2811-2814. PubMed ID: 28504030
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis.
Ciuculete DC; Popescu RA; Dan GA
Rom J Intern Med; 2021 Sep; 59(3):270-277. PubMed ID: 33913303
[TBL] [Abstract][Full Text] [Related]
25. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.
Wiczer TE; Levine LB; Brumbaugh J; Coggins J; Zhao Q; Ruppert AS; Rogers K; McCoy A; Mousa L; Guha A; Heerema NA; Maddocks K; Christian B; Andritsos LA; Jaglowski S; Devine S; Baiocchi R; Woyach J; Jones J; Grever M; Blum KA; Byrd JC; Awan FT
Blood Adv; 2017 Sep; 1(20):1739-1748. PubMed ID: 29296820
[TBL] [Abstract][Full Text] [Related]
26. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.
Jiang L; Li L; Ruan Y; Zuo S; Wu X; Zhao Q; Xing Y; Zhao X; Xia S; Bai R; Du X; Liu N; Ma CS
Heart Rhythm; 2019 Sep; 16(9):1374-1382. PubMed ID: 30959203
[TBL] [Abstract][Full Text] [Related]
27. Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Khalid S; Yasar S; Khalid A; Spiro TP; Haddad A; Daw H
Cureus; 2018 May; 10(5):e2701. PubMed ID: 30062075
[TBL] [Abstract][Full Text] [Related]
28. Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region.
Andersson ML; Johansson H; Österborg A; Månsson-Broberg A; Hansson L; Palma M
Eur J Haematol; 2023 Nov; 111(5):748-756. PubMed ID: 37565648
[TBL] [Abstract][Full Text] [Related]
29. Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.
Gustine JN; Meid K; Dubeau TE; Treon SP; Castillo JJ
Am J Hematol; 2016 Jun; 91(6):E312-3. PubMed ID: 26994323
[No Abstract] [Full Text] [Related]
30. Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS/ACC TVT Registry.
Vora AN; Dai D; Matsuoka R; Harrison JK; Hughes GC; Sherwood MW; Piccini JP; Bhardwaj B; Lopes RD; Cohen D; Holmes DR; Thourani VH; Peterson E; Kirtane A; Kapadia S; Vemulapalli S
JACC Cardiovasc Interv; 2018 Sep; 11(17):1746-1756. PubMed ID: 30190063
[TBL] [Abstract][Full Text] [Related]
31. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
Stühlinger MC; Weltermann A; Staber P; Heintel D; Nösslinger T; Steurer M
Wien Klin Wochenschr; 2020 Feb; 132(3-4):97-109. PubMed ID: 31414181
[TBL] [Abstract][Full Text] [Related]
32. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
33. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
34. Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy.
Onitilo AA; Piwuna TO; Islam N; Furuya-Kanamori L; Kumar S; Doi SAR
Clin Med Res; 2022 Mar; 20(1):16-22. PubMed ID: 35022197
[No Abstract] [Full Text] [Related]
35. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
Fradley MG; Gliksman M; Emole J; Viganego F; Rhea I; Welter-Frost A; Armanious M; Lee DH; Walko C; Shah B; Chavez JC; McLeod H; Pinilla-Ibarz J; Schabath MB
Am J Cardiol; 2019 Aug; 124(4):539-544. PubMed ID: 31208701
[TBL] [Abstract][Full Text] [Related]
36. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.
Sawhney JP; Kothiwale VA; Bisne V; Durgaprasad R; Jadhav P; Chopda M; Vanajakshamma V; Meena R; Vijayaraghavan G; Chawla K; Allu J; Pieper KS; John Camm A; Kakkar AK;
Indian Heart J; 2018; 70(6):828-835. PubMed ID: 30580852
[TBL] [Abstract][Full Text] [Related]
37. High incidence of atrial fibrillation in patients treated with ibrutinib.
Baptiste F; Cautela J; Ancedy Y; Resseguier N; Aurran T; Farnault L; Escudier M; Ammar C; Gaubert M; Dolladille C; Barraud J; Peyrol M; Cohen A; Paganelli F; Alexandre J; Ederhy S; Thuny F
Open Heart; 2019; 6(1):e001049. PubMed ID: 31168393
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ
PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921
[TBL] [Abstract][Full Text] [Related]
39. Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.
Tuomi JM; Xenocostas A; Jones DL
Can J Cardiol; 2018 Mar; 34(3):337-341. PubMed ID: 29475534
[TBL] [Abstract][Full Text] [Related]
40. Trends and Outcomes of Atrial Fibrillation-Flutter Hospitalizations Among Heart Transplant Recipients (From the National Inpatient Sample).
Voruganti D; Shantha G; Dugyala S; Pothineni NVK; Agnihotri K; Bozorgnia B; Amanullah A; Giudici M; Briasoulis A
Am J Cardiol; 2020 Jan; 125(1):87-91. PubMed ID: 31685214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
